In Episode 2 Emily is joined by Dr. Drew Pinsky.
As a 4th year med student at the University of California in the 1980s, Dr. Drew became a regular guest on the radio show “Loveline,” which catapulted his career in media. The show grew to the point of being nationally syndicated, with Drew co-hosting for over 20 years.
In this interview Emily and Drew focus on critical thinking, especially among younger audiences. Dr. Drew elaborates on the current state of discourse in society, expressing his concern about what he calls a “pandemic of irrational certitude.” He emphasizes that this certitude is often irrational, as it resists the natural uncertainty that comes with rational thinking. He points out that true rationality requires an acceptance of uncertainty and a willingness to engage in open, critical discussions.
To this day Dr. Drew maintains a private practice in addition to hosting several ongoing podcasts.
The full episode is available for Members of the BSI Medical Society or through premium membership of our YouTube channel.
Full Episode (Med Society)
Full Episode (YouTube)
LISTEN AS A PODCAST
The art and science of changing our collective conversation. This critical thinking project highlights the people who are smart enough to see the problem AND brave enough to expose it. The show pays homage to those who dare to challenge conventional wisdom.
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
